Tau Triggers Neuroinflammation, But Mechanisms Vary by Disease
In two primary tauopathies, natural killer cells invade the brain. In Alzheimer’s, a microglial antiviral response dominates, and hyperexcitability may play a role.
ALL NEWS
6493 RESULTS
Sort By:
- Most Recent
- Most Commented
Alzheimer: 100 Years and Beyond
By Jennifer Altman, based on her original report in Alzheimer Actualités, a newsletter published by the <a href="http://www.ipsen.com/homeFondation.jsp" target="_new">Ipsen Foundation</a>...
1998 Society for Neuroscience Meeting: Alois Award Winners
The organizers of this year's special interest social on Alzheimer's disease decided to stage an awards ceremony to salute scientists who had distinguished themselves in various categories not ordinarily recognized...
World Alzheimer Conference 2000: Neuroinflammation in AD
It has been a century since Alzheimer and Bielchowsky reported senile plaques (SP) in AD brain, but it was only relatively recently appreciated that SPs are embraced by reactive astrocytes and microglia...
World Alzheimer Conference 2000: Aβ Vaccine Update
Last July, Dale Schenk and colleagues from Elan Pharmaceuticals reported the remarkable observation that simple immunization of PDAPP transgenic mice...
Lecanemab Post Hoc: Is Continual Treatment Required for Cognitive Benefit?
Patients taken off the drug continue to outperform those who were never on it, and decline slows even more once treatment resumes. Cognition and plasma Aβ changes are consistent with disease-modifying effect.
Methods to Detect Amyloid Seeds Improve, Extend to Blood and Parkinson’s
Methods that trawl body fluids for amyloidogenic proteins are getting more sensitive and specific, and scientists are expanding the repertoire of oligomers they can detect.
Tau2022 Global Conference (Virtual Meeting)
P-Tau217 Clock Predicts Alzheimer’s Progression Over 30 Years At Tau2022: Unknown Functions Emerge for Tau, LRRK2 Tau Triggers Neuroinflammation, But Mechanisms Vary by Disease Tau Haplotypes Hint at Transcriptional Changes, Ferroptosis Since Tau2020 was
AD/PD 2022: Advances in Science and Therapy (Hybrid Virtual and In-Person)
Gantenerumab Prevention Trial in Sporadic Alzheimer's Begins In First for the Field, α-Synuclein PET. Only for Multiple System Atrophy Using Lecanemab Trial Data to Determine Maintenance Dose Scientists Re-Analyze Aduhelm Data, Try to Parse Who Benef
Clinical Trials on Alzheimer's Disease (CTAD) 2021 (Hybrid In-Person/Virtual)
Aduhelm Lowers Tau; Registry to Track Real-World Performance Donanemab Phase 3 Puts Plasma p-Tau, Remote Assessments to the Test Plasma Aβ—First Sign of AD, But Tough to Measure Prospectively? More Tau Antibodies Bid Adieu; Semorinemab Keeps Foot in Door
DNA Nuclease Fans the Flames of Huntington’s Disease
Rare genetic variants that blunt FAN1 activity cause rapid expansion of CAG trinucleotide repeats in somatic cells.
Is This Mutation Pathogenic? Alzforum Updates System for Making This Call
Applied to more than 500 alleles in APP, PSEN1, and PSEN2, the new classification can help scientists gauge how pathogenic, or benign, a given variant might be
NIH Summit Wraps Up with Recommendations for Research
Outcomes emphasize big data, new technology, environmental and genetic risk in hopes of enabling precision medicine.
Non-Aβ, Non-Tau Drugs Tweak Markers, Cognition in Alzheimer’s, Huntington’s
Researchers at the online AAT-AD/PD meeting touted therapies that target neuroinflammation, synapses, epigenetic regulation, or the cortisol stress response.
The Rain in Spain: Move Over Higgins, AI Spots Speech Patterns
AI-powered apps catch changes in how a person speaks that may reveal cognitive decline in frontotemporal dementia and early Alzheimer’s. Can smartphones deliver biomarkers for trial enrollment and diagnosis?
Current Filters
No filters selected